Who is sponsoring NCT02220868?

NCT02220868 is sponsored by Saint Michael's Medical Center.

What drugs are being tested in NCT02220868?

Interventions in NCT02220868: Sofosbuvir, Ribavirin, and Stribild.

What condition does NCT02220868 study?

NCT02220868 studies Hepatitis C Infection, HIV Infection.

Is NCT02220868 still recruiting?

NCT02220868 is currently completed. Last updated 3 August 2016.

Last reviewed 2016-08-03 · How we verify

NCT02220868

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study

Completed Phase 4 Last updated 3 August 2016

What this trial tests

Phase 4 trial testing Sofosbuvir, Ribavirin, and Stribild in Hepatitis C Infection in 10 participants. Completed in 1 September 2015.

Timeline

1 July 2014

Primary endpoint
1 August 2015

1 September 2015

Quick facts

Lead sponsor	Saint Michael's Medical Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 July 2014
Primary completion	1 August 2015
Estimated completion	1 September 2015
Sites	1 location across United States

Drugs / interventions tested

Sofosbuvir, Ribavirin, and Stribild — full drug profile →

Conditions studied

Hepatitis C Infection — all drugs for Hepatitis C Infection →
HIV Infection — all drugs for HIV Infection →

Sponsor

Saint Michael's Medical Center

Who can join

Adults 18 to 99, any sex, with Hepatitis C Infection or HIV Infection. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• SVR,12 defined as undetectable HCV RNA levels for 12 weeks after the completion of therapy
Time frame: 12 weeks post treatment
patients who have achieved non-detectable HCV levels 12 weeks post treatment

Sponsor's own description

The protocol will study the safety and efficacy of using sofosbuvir and ribavirin for the treatment of hepatitis c in patients taking stribild.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hepatitis C Infection

Currently open trials in the same condition.

NCT02772003 — DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection · Phase 1 · active not recruiting

Other Saint Michael's Medical Center trials

Trials by the same sponsor.

NCT04826562 — Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND) · Phase 4 · unknown
NCT02858050 — Portal-724 MEMS for Medication Adherence Patients Taking HCV Medications · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02220868 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Saint Michael's Medical Center
Last refreshed: 3 August 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02220868.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing